Biopharma Growth Kent Elastomer launched a biopharmaceutical tubing line in January 2024, signaling a strategic push into regulated life-sciences markets. Combined with ISO and SQF certifications, FDA validation, and Class VII clean rooms, this positions them to target contract manufacturers, biopharma firms, and biotech startups needing compliant, single-source tubing solutions including coextruded or latex options.

US Latex Leadership Only US manufacturer of natural latex tubing, a distinctive capability for medical devices, diagnostics, and lab kits requiring latex compatibility. This domestic niche, coupled with Made in USA and ISO/SQF/FDA-ready operations across multiple Ohio facilities, creates targeted opportunities for US-based procurement, government tenders, and healthcare customers seeking supply chain resilience.

Turnkey Capabilities Full-service tubing provider offering extrusion, coextrusion, dip molding, and assembly, with the ability to deliver turnkey kits and components. Materials include TPE, TPV, PVC, natural latex, neoprene, enabling cross-sell opportunities across medical, veterinary, dental, lab, industrial, and food/beverage segments.

Compliance Focus Strong compliance and quality posture with ISO and SQF certifications, FDA validation, and Class VII clean rooms enhances credibility with regulated customers. Coupled with leadership in quality and regulatory functions, this supports pursuing additional certifications and broader market access in medical devices and pharma.

Domestic Footprint Three Ohio facilities enabling Made in USA, domestic production, and scalable capacity for Midwest OEMs and life-sciences customers. Close proximity reduces lead times and logistic risk, offering regional supply chain advantages for medical device, biopharma, and lab equipment manufacturers.